Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is a matter of debate. We aimed to clarify whether [ malignant pleural mesothelioma patients ] with loss of BAP1 expression have better overall survival (OS) compared to BAP1 positive patients. Methods: [ BRCA1 … [Read more...]
Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature
Background: Malignant mesothelioma of the tunica vaginalis is a rare tumour which comprises less than 1% of all mesotheliomas. Case presentation: 69-years old patient with painful hard mass and hydrocele in the right scrotum to whom a right hydrocelectomy was performed. Any history of scrotal trauma or exposure to asbestos was not … [Read more...]
CD70 Expression Correlates With a Worse Prognosis in Malignant Pleural Mesothelioma Patients
Diffuse malignant mesothelioma of the pleura (MPM) is a highly aggressive tumour that typically is associated with short survival. CD70 and CD27 belong to the tumour necrosis factor (TNF) and the TNF receptor (TNFR) superfamily, respectively. Under physiological conditions, the tightly regulated interaction between CD70 and CD27 plays a … [Read more...]
Owkin’s mesothelioma AI discovers new biomarkers from lung biopsy images
By scanning thousands of tissue samples, [ Owkin’s mesothelioma AI program ] was able to help identify new types of patients with mesothelioma and predict which may respond better to certain therapies. Using whole biopsy slide images taken from nearly 3,000 patients with the aggressive and potentially fatal disease, [ Owkin’s mesothelioma AI … [Read more...]
Diagnostic Value of Biopsy Sampling in Predicting Histology in Patients With Diffuse Malignant Pleural Mesothelioma
BACKGROUND: The classification of diffuse malignant mesothelioma into epithelioid, biphasic, and sarcomatoid types is based on histologic patterns. The diagnosis is made on biopsies, and because of intratumoral heterogeneity, they may not be representative of the entire tumor. The number and volume of biopsies needed to reach diagnostic accuracy in … [Read more...]
Dr. Goldberg Discusses the Diagnosis of Mesothelioma (Short Video)
Sarah B. Goldberg, MD, MPH, assistant professor of medicine, Yale School of Medicine and Yale Cancer Center, discusses the diagnosis of mesothelioma. This is an extremely rare disease that is usually seen in patients with prior asbestos exposure, Goldberg says. However, mesothelioma can be seen occasionally in patients without prior exposure to … [Read more...]
Malignant pleural mesothelioma presenting with remitting–relapsing pleural effusions: report of two cases
Pleural effusions are common and are associated with malignancy in one sixth of cases. Malignant pleural effusion (MPE) is typically persistent and progressive, prompting further investigations if the initial tests are not diagnostic. A spontaneously remitting effusion is commonly presumed to be benign, and further investigations may not be … [Read more...]
Chemical profiling of primary mesothelioma cultures defines subtypes with different expression profiles and clinical responses
Finding new treatment options for patients with malignant pleural mesothelioma is challenging due to the rarity and heterogeneity of this cancer type. The absence of druggable targets further complicates the development of new therapies. Current treatment options are therefore limited and prognosis remains poor. Experimental Design: We performed … [Read more...]
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, soluble mesothelin-related peptide (SMRP), cytokeratin 19 fragment (CYFRA 21–1) and carcinoembryonic antigen (CEA), and the utility of combining chest computed tomography (CT) findings with these biomarkers, in diagnosing malignant pleural mesothelioma … [Read more...]
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
Background Analysis of the International Association for the Study of Lung Cancer (IASLC) Malignant Pleural Mesothelioma (MPM) database revealed that clinical (cTNM) staging minimally stratified survival and was discrepant with pathological (pTNM) staging. To improve prognostic classification of MPM, alternative staging models based on … [Read more...]